If your patient is taking any of the products below:

• Please have them consider changing to a different medication for their condition.
• Remind them to return the recalled medication to their pharmacy.

Below are recent nationwide medication recalls and notices:

• Ranitidine Tablets, 150 mg and 300 mg, and Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL
  Manufacturer: Amneal Pharmaceuticals, LLC
  Recall Date: 11/08/2019
  Reason: Due to potential N-Nitrosodimethylamine (NDMA) amounts being above levels established by the FDA.
  FDA Notice
• Ranitidine Tablets 150mg, Ranitidine Capsules 150 mg, Ranitidine Capsules 300 mg and Ranitidine Syrup 15 mg/mLRanitidine Tablets, Capsules, and Syrup
  Manufacturer: Aurobindo Pharma USA, Inc.
  Recall Date: 11/06/2019
  Reason: Due to the detection of Nitrosodimethylamine (NDMA) impurity.
  FDA Notice
• Ranitidine Syrup (Oral Solution, USP), 15 mg/mL
  Manufacturer: Lannett Company, Inc.
  Recall Date: 10/25/2019
  Reason: Due to levels of N-Nitrosodimethylamine (NDMA) being above the levels recently established by the FDA.
  FDA Notice
• Ranitidine Tablets & Capsules
  Manufacturer: Dr. Reddy’s Laboratories Ltd.
  Recall Date: 10/23/2019
  Reason: Contamination with N-Nitrosodimethylamine (NDMA) above the levels established by the FDA.
  FDA Notice
• Losartan Potassium 50mg and Losartan Potassium/Hydrochlorothiazide combination Tablets 50mg/12.5mg, 100mg/12.5mg and 100mg/25mg
  Recall Date: 06/26/2019
  Manufacturer: Macleods Pharmaceuticals, Ltd.
  Reason: Detection of trace amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) above the interim acceptable daily intake levels released by the FDA.
  FDA Notice 
• Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg
  Recall Date: 02/22/2019
  Manufacturer: Macleods Pharmaceuticals, Ltd.
  Reason: Detection of trace amounts of an unexpected impurity (NDEA) above the interim acceptable daily intake levels released by the FDA.
  FDA Notice 
• Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
  Recall Date: 01/22/19
  Manufacturer: Torrent Pharmaceuticals Limited
  Reason: Detection of trace amounts of an N-nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA.
  FDA Notice 
• Irbesartan and Irbesartan HCTZ Tablets
  Recall Date: 01/18/2019
  Manufacturer: Prinston Pharmaceutical Inc. dba Solco Healthcare LLC
  Reason: Detection of trace amount of N-nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA.
  FDA Notice
• Valsartan and Valsartan-HCTZ Tablets, USP
  Recall Date: 07/18/2018
  Manufacturers: Prinston Pharmaceuticals, and TEVA Pharmaceuticals.
  Reason: It has been found that the recalled products for impurity detected. This may cause unexpected health risks.
  FDA Notice – Prinston Pharmaceuticals
  FDA Notice – TEVA Pharmaceuticals

• Provider Alert: New Boxed Warning for Lunesta (eszopiclone), Sonata (zaleplon), Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist (zolpidem) (05/23/19)
• Provider Alert: Legacy Pharmaceutical Packaging, LLC – Losartan Potassium Tablets Medication Recall (03/15/19)
• Provider Alert: EpiPen Use (08/21/2018)
• Provider Alert: Levothyroxine and Liothyronine (Thyroid Tablets, USP) Medication Recall (08/09/2018)
• Provider Alert: Rugby Diocto Medication Recall (8/2017)
• Provider Alert: Hospira Issues a Voluntary Nationwide Recall (6/15/17)
• Provider Alert: All Topical Products made by Phillips Company Medication Recall (6/9/2017)
• Provider Alert: All Lots of Diocto Liquid, 50 mg/5 mL for NCD 0536-0590-85 Medication Recall (07/15/2016)
• Provider Alert: All Medications Compounded by Reliable Drug Medication Recall (3/25/2016)
• Provider Alert: Amikacin Sulfate Injection 1 gram per 4mL Medication Recall (03/09/2016)
• Provider Alert: Fluconzaole Injection 200mg per 100mL Medication Recall (03/01/2016)
• Provider Alert: Acetaminophen Tablets, 500mg Medication Recall (10/14/2015)
• Provider Alert: Auvi-Q Medication Recall (10/28/2015)

• DUR: What’s New and Ongoing Projects
• Right Care Initiative – California Statewide Goals using HEDIS® measures (April 2019)
• CDC – Advisory Committee on Immunization Practices (ACIP): Recommendations (March 2019)
• CDPH – Prevention Forward (March 2019)
• Standards of Medical Care in Diabetes – 2019 Abridged for Primary Care Providers (2019)
• 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (2019)
• Medicaid & CHIP in California – Adult Core Set Reporting (2019)
• Health Affairs: One In Five Fewer Heart Attacks: Impact, Savings, And Sustainability In San Diego County (September 2018)
• UC Davis Health – Health plans that shared best practices improved hypertension control for low-income Californians (July 2017)
• CDC – Adult Vaccination Resources for Provider Practices (May 2016)
• Be There San Diego. Simplified Hypertension Treatment Approach (April 2014)
• DHCS – Medi-Cal Medication Safety
• Food & Medication Administration (FDA) – Medication Safety Bulletins archive

• FDA Recalls, Market Withdrawal Alerts
• FDA Recalls (Biologics)
• Risk Evaluation and Mitigation Strategies (REMS)
• Patient Safety Resource Center